tions. 5 Susceptibility categories were defined in accordance with the following MIC breakpoints recommended by the National Committee for Clinical Laboratory Standards:
6 third-and fourth-generation cephalosporins and cefoxitin, susceptible, 8 
-Lactamase assay
HK1 and HK2 were grown in Mueller-Hinton broth and the cells were harvested by centrifugation, washed with sodium phosphate buffer and sonicated. The supernatants were assayed spectrophotometrically for -lactamase activity with nitrocefin (0.10 mM) in 50 mM sodium phosphate buffer (pH 7.0) as described previously. 7 The protein concentrations were determined by the method of Lowry with bovine serum albumin as the standard. 8 
Polymerase chain reaction
A polymerase chain reaction (PCR) technique, described previously by M'Zali et al. 9 but modified to allow an annealing temperature of 51°C instead of 60°C, was used to amplify a 475 bp sequence of the SHV gene. A second PCR technique, described previously, 10 was used to amplify a 503 bp sequence of the TEM gene. Plasmid DNA was used as a template.
Selection of mutants
HK1 and HK2 were grown in Mueller-Hinton broth until the mid-logarithmic phase of growth was reached. Aliquots (100 mL) of each strain were inoculated on to Mueller-Hinton agar containing meropenem at a concentration equivalent to 4 MIC or imipenem at a concentration equivalent to 2 MIC for HK1 and 8 MIC for HK2. (No mutants were selected following incubation of HK1 in the presence of imipenem at a concentration equivalent to 8 MIC.) The plates were incubated overnight at 37°C. The frequencies of mutation were determined by diluting the cultures used for selecting the mutants 10 14 -fold, inoculating on to antibiotic-free agar and, following overnight incubation, counting the number of viable bacteria.
Sodium dodecyl sulphate-polyacrylamide gel electrophoresis analysis
HK1 and HK2 were grown in Mueller-Hinton broth and the cells were washed with Tris-HCl (10 mM)-MgCl 2 (5 mM), pH 7.3, and sonicated. Outer membrane protein (OMP) preparations were obtained by removing cytoplasmic membranes with 2% sodium lauryl sarcosinate and ultracentrifuging. The OMPs were separated by SDS-PAGE and the gels were stained with Coomassie blue as described previously.
1

Results
The MICs for HK1 and HK2 are summarized in the Table. Both isolates were susceptible to cefoxitin, cefepime, the carbapenems, amikacin and ciprofloxacin and resistant to gentamicin. In addition, HK1 was susceptible to all of the other cephalosporins tested, while HK2 was susceptible to cefotetan and resistant to the third-generation cephalosporins and cefpirome. Of the commercially availablelactam/ -lactamase inhibitor combinations (co-amoxiclav, ampicillin/sulbactam and piperacillin/tazobactam), HK1 was susceptible to co-amoxiclav, of intermediate susceptibility to piperacillin/tazobactam and resistant to ampicillin/sulbactam, whereas HK2 was resistant to all three formulations. Clavulanic acid restored the activity of ceftazidime against HK2 and further increased the susceptibility of HK1 to this agent. The -lactamase activity of HK2 was more than twice that of HK1 (Table) . Finally, PCR with SHV-and TEM-specific primers confirmed the presence of both types of ESBL in each of the isolates.
Following incubation of HK1 and HK2 in the presence of meropenem at concentrations equivalent to 4 MICs for these strains, HK1 mutants were selected at frequencies of 4 10 -12 and HK2 mutants at frequencies of 1 10 -11 . Exposure of HK1 and HK2 to imipenem at concentrations equivalent to 2 MIC and 8 MIC respectively yielded mutants at the same frequencies as those selected with meropenem. The MICs for the mutants are shown in the Table. For the meropenemselected mutants of HK1 and HK2 (HK1m and HK2m), the MICs of meropenem were 16 and 64 times, respectively, greater than those for the parent strains. In contrast, the MICs of imipenem for these mutants were no more than four times those for HK1 and HK2. For the mutants selected following incubation in the presence of imipenem (HK1i and HK2i), the MICs of imipenem and meropenem did not exceed those for the parent strains by more than four-fold. With regard to the other antibiotics tested, the MICs of most of the -lactams, including the -lactam/ -lactamase inhibitor combinations, for HK1m and HK2m were four to eight times those for the parent strains; with one exception (cefotetan and HK2m), the Porin-deficient K. pneumoniae selected by meropenem mutants were categorized as resistant to these antibiotics. The MICs of all of the -lactams tested for the imipenemselected mutants, on the other hand, were the same as, or similar to, those for the parent strains. The -lactamase activities of the mutants were also similar to those of the parent strains. No differences were observed between the parent and mutant strains in terms of the MICs of the non--lactam antibiotics tested. SDS-PAGE analysis revealed that a protein present in both parent strains was absent in HK1m and HK2m (Figure) . This protein, however, was present in HK1i and HK2i (data not shown).
Discussion
Resistance to carbapenems in K. pneumoniae isolates is attributed to the absence or reduced expression of OMPs, to hyperproduction of SHV ESBLs or to plasmidmediated AmpC-type -lactamases. 3, 4 Martínez-Martínez et al. 1 demonstrated that K. pneumoniae strains possess two major OMPs of ca. 32 and 35 kDa respectively; a third OMP of ca. 36 kDa has also been identified in some isolates. It has been suggested that the 35 and 36 kDa proteins are highly likely to be porins, 1, 11 while the 32 kDa protein may correspond to OmpA of Escherichia coli which is not a porin and, therefore, probably does not contribute to antibiotic resistance. The SDS-PAGE analysis performed here revealed the presence in both the parent and mutant strains of major OMPs in the 31-45 kDa range. This observation suggests that the protein that was missing from the meropenem-derived mutants is a porin.
The meropenem-selected mutants in the present study 823 exhibited resistance to all of the cephalosporins tested, with the exception of cefotetan which is not hydrolysed by ESBLs, and to the commercially available -lactam/ -lactamase inhibitor combinations, possibly because of the combined effects of ESBL production and the impaired permeability attributable to the missing porin. In contrast to imipenem, meropenem appeared to select porin-deficient mutants in vitro from the two ESBLproducing strains of K. pneumoniae, and these mutants exhibited markedly reduced susceptibility to meropenem, but not to imipenem. Cornaglia et al. 12 observed that penetration of meropenem into porin-deficient mutants of Enterobacter cloacae was 25-fold slower than that into the parent strain which expressed porin proteins, whereas the penetration rate of imipenem was only seven-fold lower. Normally, the rate of penetration of meropenem into porin-deficient isolates of E. cloacae is seven-fold lower than that of imipenem, while the two carbapenems penetrate into porin-expressing strains at the same rate. When these factors are taken into account, the marked increase in the MICs of meropenem, but not imipenem, in our porin-deficient K. pneumoniae mutants is probably related to the impaired penetration of meropenem. However, other mechanisms, such as active efflux, might have contributed to the reduced activities of the carbapenems in our porin-deficient isolates, as previously observed in Pseudomonas aeruginosa; 13 the role of altered penicillin-binding proteins also cannot be discounted.
To our knowledge, this is the first report of the in-vitro selection of porin-deficient mutants of K. pneumoniae following exposure to meropenem.
